incretin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-14. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
=== Organochlorides === The first and best known organochloride, DDT, was first synthesised by Othmar Zeidler. Swiss scientist Paul Müller found DDTs insecticide properties. For this discovery, he was awarded the 1948 Nobel Prize for Physiology or Medicine. DDT was introduced in 1944. It functions by opening sodium channels in the insect's nerve cells. The contemporaneous rise of the chemical industry facilitated large-scale production of chlorinated hydrocarbons including various cyclodiene and hexachlorocyclohexane compounds. Although commonly used in the past, many older chemicals have been removed from the market due to their health and environmental effects (e.g. DDT, chlordane, and toxaphene).
=== July === 24 July – The United States imposes a 12.5% tariff on Brazil, citing the presence of alleged forced labour in the supply chain. The United States Government also imposes tariffs ranging between 10 and 12.5% on 59 other countries. 27 July – The Theatro da Paz in Belem and the Amazon Theatre in Manaus are designated as UNESCO World Heritage Sites.
== Healthcare == UPMC Children's Hospital of Pittsburgh Community Health Partnerships, Scotland Certified Health Physicist, United States, a specialist in radiation protection and safety Centre for Health Protection, an agency of Hong Kong Cricohyoidopexy, a surgical procedure
Sources: en.wikipedia.org
In 2012, a laser engraved panel featuring Wheatley was launched aboard the Japan Aerospace Exploration Agency (JAXA)'s Kounotori 3 mission on its way to resupply the International Space Station. In April 2011, series of Portal-themed DLC levels were added to the game The Ball. A few Portal characters, including Chell and P-Body, feature as avatar customization items in the game Fall Guys for 5 crowns each. The portal gun is one of several weapons used alongside ones from other game and film franchises in a climactic fight for the 2021 film Free Guy which takes place within a video game. A reference to GLaDOS appears in a sub-quest in Cyberpunk 2077 as a murderous AI driving a taxi and eventually tries to kill the protagonist. In 2022, GEICO released a commercial entitled "The Gecko Visits Portal", featuring elements from the Portal games such as an unreleased test chamber shown in trailers for Portal 2, with McLain reprising her role as GLaDOS. Rocket League released free DLC that includes a variety of items from the Portal series available for vehicle customization. Evil Genius 2: World Domination includes a free Portal themed expansion pack which adds Portal-themed rooms and traps to the game. Escape Simulator features a free Portal Escape Chamber DLC in which players will need to escape from the Aperture Science Laboratories by solving various puzzles.
=== Brain === The apelin receptor is also expressed in the neurons of brain areas involved in regulating water and food intake. Apelin injection increases water intake and apelin decreases the hypothalamic secretion of the antidiuretic hormone vasopressin. This diuretic effect of apelin in association with its hypotensive effect participates in the homeostatic regulation of body fluid. Apelin is also detected in brain areas which control appetite, but its effects on food intake are very contradictory.
The country had fielded black troops during World War I, but since then had retained them only within the BSAP. A nucleus of airmen existed in the form of the Southern Rhodesian Air Force (SRAF), which in August 1939 comprised one squadron of 10 pilots and eight Hawker Hardy aircraft, based at Belvedere Airport near Salisbury. The occupation of Czechoslovakia by Nazi Germany in March 1939 convinced Huggins that war was imminent. Seeking to renew his government's mandate to pass emergency measures, he called an early election in which his United Party won an increased majority. Huggins rearranged his Cabinet on a war footing, making the Minister of Justice Robert Tredgold Minister of Defence as well. The territory proposed forces not only for internal security but also for the defence of British interests overseas. Self-contained Rhodesian formations were planned, including a mechanised reconnaissance unit, but Tredgold opposed this. Remembering the catastrophic casualties suffered by units such as the Royal Newfoundland Regiment and the 1st South African Infantry Brigade on the Western Front in World War I, he argued that one or two heavy defeats for a white Southern Rhodesian brigade might cause crippling losses and have irrevocable effects on the country as a whole. He proposed to instead concentrate on training white Rhodesians for leadership roles and specialist units, and to disperse the colony's men across the forces in small groups. These ideas met with approval in both Salisbury and London and were adopted.
== Absorption, metabolism, and excretion == Tocotrienols and tocopherols, the latter including the stereoisomers of synthetic alpha-tocopherol, are absorbed from the intestinal lumen, incorporated into chylomicrons, and secreted into the portal vein, leading to the liver. Absorption efficiency is estimated at 51% to 86%, and that applies to all of the vitamin E family – there is no discrimination among the vitamin E vitamers during absorption. Bile is necessary for chylomicron formation, so disease conditions such as cystic fibrosis result in biliary insufficiency and vitamin E malabsorption. When consumed as an alpha-tocopheryl acetate dietary supplement, absorption is promoted when consumed with a fat-containing meal. Unabsorbed vitamin E is excreted via feces. Additionally, vitamin E is excreted by the liver via bile into the intestinal lumen, where it will either be reabsorbed or excreted via feces, and all of the vitamin E vitamers are metabolized and then excreted via urine. Upon reaching the liver, RRR-alpha-tocopherol is preferentially taken up by alpha-tocopherol transfer protein (α-TTP). All other forms are degraded to 2'-carboxethyl-6-hydroxychromane (CEHC), a process that involves truncating the phytic tail of the molecule, then either sulfated or glucuronidated. This renders the molecules water-soluble and leads to excretion via urine. Alpha-tocopherol is also degraded by the same process, to 2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychromane (α-CEHC), but more slowly because it is partially protected by α-TTP.
Sources: en.wikipedia.org
Gynecomastia induced by spironolactone usually regresses after a few weeks following discontinuation of the medication. However, after a sufficient duration of gynecomastia being present (e.g., one year), hyalinization and fibrosis of the tissue occurs and drug-induced gynecomastia may become irreversible.
EU Foreign Policy chief Josep Borrell said that the total amount of weaponry sent to Ukraine by the bloc since March 2023 had reached 220,000 artillery shells and 1,300 missiles. The SBU launched a criminal investigation against Maj. Gen. Andrey Ruzinsky, commander of the Russian Baltic Fleet's 11th Army Corps for his role in the invasion and occupation of parts of Kharkiv Oblast and subsequent atrocities, particularly in Balakliia. The Prosecutor General of Ukraine also opened an investigation into the role of Belarus in the forced transfer of children from Russian-occupied territories, following a report by the exiled Belarusian opposition group National Anti-Crisis Management, alleging that 2,150 Ukrainian children, including orphans aged six to 15, were taken to at least three so-called recreation camps and sanatoriums on Belarusian territory. Polish Defence Minister Mariusz Błaszczak said that the government was ready to train Ukrainian pilots on F-16 aircraft but it rejected supplying F-16s to Ukraine, fearing a "degrading effect" on the Polish Air Force. The Russian Defence Ministry said it had deployed an Su-27 fighter jet to intercept and prevent two US Air Force B-1B strategic bombers from entering its airspace over the Baltic Sea. The Pentagon later confirmed the incident, saying that aircraft were taking part in a planned exercise and the Russian fighter's interaction with the planes was "safe and professional".
If the microbiology lab result did not support the use of vancomycin, it was suggested to change the medication to something appropriate as under the Center for Disease Control CDC guidelines. The use of CDR's could help monitor infectious diseases in the hospital and the appropriate prescribing based on lab results. The use of Clinical Data Repositories could provide a wealth of knowledge about patients, their medical conditions, and their outcome. The database could serve as a way to study the relationship and potential patterns between disease progression and management. The term "Medical Data Mining" has been coined for this method of research. Past epidemiological studies may not have had as complete of information as that which is contained in a CDR, which could lead to inconclusive data/results. The use of medical data mining and correlative studies using the CDR could serve as a valuable resource helping the future of healthcare in all facets of medicine. The idea of data mining a CDW was used for screening variables that were associated with diabetes and poor glycemic control. It allowed for novel correlations that may have not been discovered without this method. One potential use of a clinical data repository would be for clinical trials. This would allow for researchers to have all the information from a study in one place as well as let other researchers benefit from the data to further innovation. They would also be advantageous since they are digital and real-time.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.